No Data
No Data
Sanyuan Biology: 2024 Semi-Annual Report
Sanyuan Biology: 2024 Semi-Annual Report Summary
San Yuan Biological (301206.SZ): The net income in the first half of the year was 51.9138 million yuan, a year-on-year increase of 55.82%.
GeLongHui, August 29th | Sanyuan Bio (301206.SZ) released its 2024 interim report, with a total operating income of 0.377 billion yuan during the reporting period, a year-on-year increase of 60.15%; the net income attributable to the shareholders of the listed company was 51.9138 million yuan, a year-on-year increase of 55.82%; the net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 51.1623 million yuan, a year-on-year increase of 56.32%; and the basic earnings per share was 0.26 yuan.
Sanyuan Biology (301206.SZ) released its performance for the first half of the year, with a net income of 51.9138 million yuan, a year-on-year increase of 55.82%.
Sanyuan Biology (301206.SZ) released its 2024 interim report, with the company achieving a revenue of 3...
Sanyuan Biotech (301206.SZ) currently has the capability to produce high-quality stevia sugar in small quantities.
On August 15th, Gelonhui reported that Sanyuan Biology (301206.SZ) stated on its investor interaction platform that the company currently has a small-scale production capacity for high-quality sweeteners and is conducting market promotion. In the future, the company will steadily expand production capacity based on market demand and feedback to ensure that production capacity expansion conforms to actual market conditions.
Sanyuan Biotech (301206.SZ): The company produces ribavirin M through comprehensive enzyme method.
On August 15th, Gelonghui reported that Sanyuan Biology (301206.SZ) stated on the investor platform that the company does not produce traditional sweeteners, but produces stevioside M through full-enzyme production. Currently, it has just started small-scale production and promotion, and the reference significance of gross margin is limited. In the future, with the increase in market demand and gradual expansion of production, the gross margin of stevioside M is expected to effectively improve the company's overall profitability.
No Data